Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) FCF Margin (2022 - 2023)

Pasithea Therapeutics (KTTA) has disclosed FCF Margin for 2 consecutive years, with 886.34% as the latest value for Q2 2023.

  • Quarterly FCF Margin rose 1341574.0% to 886.34% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 4000.3% through Mar 2024, down 82944.0% year-over-year, with the annual reading at 2466.64% for FY2022, 1874941.0% up from the prior year.
  • FCF Margin hit 886.34% in Q2 2023 for Pasithea Therapeutics, down from 5459.15% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 5459.15% in Q1 2023 to a low of 15771.77% in Q1 2022.